Supernus Pharmaceuticals (SUPN) Revenue (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has reported Revenue for 16 consecutive years, with $219.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 32.4% year-over-year to $219.1 million in Q2 2026; TTM through Jun 2026 was $788.2 million, a 18.5% increase from a year earlier, with the FY2025 full-year figure at $719.0 million, up 8.63% from the prior year.
• Revenue was $219.1 million for Q2 2026 at Supernus Pharmaceuticals, up from $211.6 million in the prior quarter.
• Over five years, Revenue peaked at $219.1 million in Q2 2026 and troughed at $135.6 million in Q2 2023.
• A 5-year average of $169.1 million and a median of $167.3 million in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue dropped 20.28% in 2023 and soared 32.4% in 2026, its largest moves.
• Over 5 years, Revenue stood at $167.3 million in 2022, then dropped by 1.8% to $164.3 million in 2023, then rose by 5.99% to $174.2 million in 2024, then increased by 21.48% to $211.6 million in 2025, then increased by 3.54% to $219.1 million in 2026.
• The last three Revenue figures came in at $219.1 million (Q2 2026), $211.6 million (Q4 2025), and $192.1 million (Q3 2025), per Business Quant data.